Comparison of18F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma

• DOI: 10.1002/pbc.26014
• Publication Date: 2016-04-15T16:24:48Z
• Authors: Caitlin Hurley; M. Beth McCarville; Barry L. Shulkin; Shenghua Mao; Jianrong Wu; Fariba Navid; Najat C. Daw; Alberto S. Pappo; Michael W. Bishop
• Keywords: Bone scintigraphy

Background Bone scintigraphy (BS) is used to detect osseous metastases in osteosarcoma. 18F-fluorodeoxyglucose-positron emission tomography–computed tomography (18F-FDG-PET-CT) being increasingly for staging. We compared the sensitivity, specificity, and diagnostic accuracy of 18F-FDG–PET-CT BS detecting Methods retrospectively reviewed 39 patients with osteosarcoma who had paired PET–CT at diagnosis and/or first recurrence from 2003 2012. Imaging studies were by two pediatric imaging specialists blinded results opposing modality reference standard. Reviewers categorized lesions as benign, malignant, or indeterminate. Reference standard lesion histology was biopsy clinical follow-up. Diagnostic performance PET–CT, BS, combined modalities determined. Results There 40 examinations 65 distant evaluated. Median age 12 years (range 5–19 years). Four 15 (two biopsied 13 clinically), five (one clinically). For sites, 79%, 89% 86% 32%, 96%, 77% 95%, 85%, 88% PET–CT/BS combined. Sensitivity superior (P = 0.035); < 0.001) but not better than alone 0.25). Specificity approached significance 0.063). Examination-based analysis yielded similar between individual modalities. Conclusions 18F-FDG–PET–CT demonstrated sensitivity over metastases, supporting use staging